Start here if you're new
what it is
Koru sells portable pumps and accessories that let patients get certain drug infusions at home instead of a clinic.
how it gets paid
Last year Koru Med Systems made $41M in revenue. FREEDOM60 syringe drivers was the main engine at $16M, or 39% of sales.
why it's growing
Revenue grew 22.2% last year. The quarter showed sharp top-line acceleration, with revenue up 191% vs. prior year.
what just happened
Revenue hit $30M, while gross margin held at 62.1%.
At a glance
B balance sheet — gets the job done, barely
50/100 earnings predictability — expect surprises
0.5x trailing p/e — the market's not buying it — or you found a deal
-$0.13 fy2024 eps est
$34M fy2024 rev est
xvary composite: 55/100 — below average
What they do
Koru sells portable pumps and accessories that let patients get certain drug infusions at home instead of a clinic.
Koru wins by making home infusion easier inside a market the FDA heavily polices. FDA quality system compliance (meeting safety rules → proving your device can legally be used → fewer rivals get in fast) matters when the company has only 80 employees and still sells a full delivery system. If your care happens at home, convenience is the moat.
How they make money
$41M
annual revenue · their business grew +22.2% last year
FREEDOM60 syringe drivers
$16M
FreedomEdge syringe drivers
$8M
Precision flow rate tubing
$9M
HIgH-Flo safety needle sets
$6M
Other accessories
$2M
The products that matter
portable infusion pump platform
FreedomEdge Infusion System
$41M annual revenue base
This is the clearest product anchor on the page. The company produced $41M in annual revenue last year, and the market will give this platform the credit if that number keeps climbing.
core platform
gross profit engine
High-margin device economics
62.1% gross margin
Gross margin means revenue left after direct product costs. KORU kept about 62 cents of each revenue dollar. In human-speak: the product itself is not the obvious problem. Scaling the company around it is.
economics
execution checkpoint
Path to the $50M target
$50M revenue target
The page gives you a target but not a second major engine behind it. That makes the bet unusually clear. Management has to turn one credible platform into a larger business without losing margin or clarity.
execution test
Key numbers
$41M
trailing revenue
That is the real sales base today, and it was up 22.2% vs. prior year, which tells you demand is not the problem.
7.2%
operating margin
Operating margin (profit after running the business → what the core machine earns → still negative here) says Koru has not turned growth into steady profit.
62.1%
gross margin
Gross margin (sales left after product costs → your room to pay everyone else → pretty healthy here) says the product economics are better than the bottom line.
$3M
long-term debt
Debt was just $3M, or 1% of capital, which means the balance sheet is not the main problem.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 15 / 100
- long-term debt $3M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for KRMD right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $30M, while gross margin held at 62.1%.
The quarter showed sharp top-line acceleration, with revenue up 191% vs. prior year. The quiet part is that full-year EPS still landed at -$0.13 in 2024, so scale has not fixed profitability yet.
$30M
revenue
$0.05
eps
62.1%
gross margin
the number that mattered
$30M matters because it is nearly 73% of the full $41M trailing revenue base, which shows just how lumpy this story looks in reported periods.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
KRMD's risk profile is specific, not theoretical. The biggest threat is a leadership handoff arriving before the business fully proves it can scale from $41M toward the stated $50M target.
med
CEO transition risk
A new CEO takes over on July 1, 2026. In a company this small, strategy, sales rhythm, and disclosure quality can all change faster than investors expect.
If the handoff slows progress toward $50M in revenue, the stock loses the cleanest operating marker on the page.
med
Product concentration
The snapshot points mainly to the FreedomEdge Infusion System and gives you very little segmentation beyond that. That is another way of saying you likely own a concentrated product story.
When one platform carries most of the narrative, any slowdown hits revenue confidence, margin confidence, and valuation confidence at the same time.
med
Thin disclosure keeps the discount alive
Analyst target data is sparse, institutional ownership adds little signal, and even the revenue references on the page run from $34M to $41M depending on the field.
Information gaps can keep a stock cheap longer than management wants. They also make it easier for the market to overreact when one update disappoints.
The combined risk picture is simple: you have a $198M company with $41M in annual revenue, 62.1% gross margin, and a leadership change ahead. If growth slips while the handoff gets messy, multiple expansion is not the main issue. Trust is.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
july 1, 2026 CEO handoff
This is not a ceremonial date. In a company this small, leadership change can show up in guidance tone, sales execution, and capital allocation quickly.
metric
progress from $41M toward the $50M target
That is the cleanest operating scoreboard on the page. If revenue stalls well short of it, the story shifts from scale to explanation.
trend
gross margin holding near the current 62.1%
You already know the product economics are decent. The next question is whether growth arrives without handing those economics back.
risk
whether disclosures get clearer or stay thin
When analyst and ownership data add little signal, management communication has to do more work. Better detail would narrow the guessing range around this business.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, there is no clean wall street consensus to lean on.
risk profile
volatile
price stability is 15 / 100. In plain English: the chart can move harder than the business fundamentals on any given update.
chart momentum
range-driven
the 52-week range runs from $2 to $7, and the stock sits at $6.07. You are closer to the top of the band than the bottom.
earnings predictability
50/100
That score says the numbers can still wobble. For you, that means each quarter matters more than it would in a mature compounder.
source: institutional data
Institutional activity
institutional ownership data for KRMD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive